Aurobindo Pharma’s total income Rs 549.42cr

Published on Wed, Jan 30, 2008 at 18:29 |  Source : Moneycontrol.com

Updated at Wed, Jan 30, 2008 at 20:21  

16195 Investors following Aurobindo Pharm. Share this News with them.
0
0
Share on Tumblr

RELATED NEWS

ALSO READ

Aurobindo Pharma is pleased to report its Q3 financials:

 

Q3 Standalone Financials:

Total Income Rs.549.42 Crs. (Rs.511.86 Crs.), the EBITDA Rs.93.58 Crs. (Rs.90.49 Crs.) and Net Profit Rs.55.25 Crs. (Rs.60.12 Crs.).

 

The sales in Q3 were impacted mainly due to lower off take of SSP products on account of fluctuation in Pen-G prices and continued appreciation of Rupee Vs USD.

 

The Company has completed the transfer of product Dossiers/IPRs to its European Subsidiary. Consequently there is increased provision for the tax. The benefits of globalization of IPRs will accrue in the coming years.

 

For the nine months ended 31st December 2007, the Total Income, EBITDA and Net Profit stand at Rs.1711.53 Crs (1395.71), Rs.325.82 Crs (241.34) and Rs.214.70 Crs (150.97) respectively.

 

To view detailed press release click on the attachment. 

 

Sourced From: Aurobindo Pharma Limited

  

Trending News

Business News

Recharge your Tata Docomo prepaid card by tweeting at them
IT dept freezes Kingfisher Airlines' bank a/c, again "IT dept freezes Kingfisher Airlines' bank a/c, again"

Team Anna sticks to claims as PM hits back strongly

MS Sahoo Says On CNBC-TV18 New Guidelines Are An Improvement Over The Old Ones

The latest earning numbers FIRST on CNBC-TV18
Videos

May 29 2012, 12:19

Expect Tata Motors Q4 PAT at Rs 4200 cr: StanChart

- in Brokerage Results Estimates

Interviews

May 29 2012, 22:37 | Source: CNBC-TV18

Due diligence not applied in Reebok 2010 probe: Assocham  

May 29 2012, 17:34 | Source: CNBC-TV18

Will raise Rs 250cr via ECB route next year: Hind Copper  

Subscribe to

Moneycontrol Newsletters

Moneycontrol.com offers you a choice of various sectoral and other newsletters for FREE!